Janssen Search
Search results
Fighting Disease with Community Support
Article Type: Infectious Diseases & Vaccines Expanding Community Support Since 2010, Janssen has been supporting community development in Bangladesh, in partnership with the non-governmental organizations Friendship and the Max Foundation. The ...
Oral Cavity Oropharyngeal Cancer
Partnership to Intercept Oral Cavity/Oropharyngeal Cancer The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to ...
Neuroscience
Neuroscience Neuroscience Nerve fibers Neuroscience Discovering Neuroscience Innovation Neuroscience Development Capabilities Neuroscience Product Commercialization Neurodegenerative Disorders: Utilizing biomarker sciences to drive disease understanding, ...
Patrik Ringblom
PATRIK RINGBLOM GLOBAL COMMERCIAL STRATEGY LEADER, ONCOLOGY Patrik Ringblom is the Global Commercial Strategy Leader for Oncology and is responsible for setting and executing the Oncology strategy, building disease area strongholds, and business ...
Transparency
Rhonda Fenwick, Time is Now I Trade Association Memberships Transparency of Clinical Trial Data Investigator Databank: Cross-Industry Collaboration Post-Marketing Requirements Janssen Signs with Yale Open Data Access Link – Research Ethics Code Link – ...
Our Diabetes & Cardiovascular Affiliates
Johnson & Johnson in Diabetes & Cardiovascular The various Johnson & Johnson Family of Diabetes Companies and Cardiovascular Care are working together to bring innovative solutions to meet the needs of people affected by diabetes and their ...
Commercialization of Our Medicines
Commercialization: Ensuring the Reach of Our Medicines to Patient Populations on a Global Scale “I’m deeply inspired by the legacy of this team, which for more than two decades has been a world leader in the development of transformational medicines, ...
Tumor Immunoenvironment
Apr 02, 2015 Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical relationships between cancer cells and the tumor microenvironment, * with ...
Partner With DIA
Article Type: Disease Interception Accelerator Partner with the Disease Interception Accelerator Collaboration is essential. Therefore, we are focused on cultivating external partnerships that will complement and propel disease interception strategies. ...
Tumor Microenvironment in Oncology
Tumor Microenvironment We focus our efforts on a clearly defined scientific approach. Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical ...